ACTRN12623000555651尚未招募3 期
The feasibility of REducing Cognitive decline and dementiA by Lowering bLood pressure in healthy adults aged 70 years and over Pilot (RECALL Pilot)
适应症
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Prevention
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 70 Years 至 o limit（—）
- 性别
- All
入选标准
- •1.Adults (age greater than or equal to 70 years)
- •2.Proficient in English (able to provide informed consent)
- •3.Participants cannot be taking any ACE Inhibitors, spironolactone, eplerenone, amiloride, or triamterene or the medications contained the in the trial treatment at a dose that would mean taking the trial treatment resulted in a more than maximum dose of angiotensin receptor blockers, thiazide like diuretics or dihydropyridine calcium channel blockers nor any medication contraindicated for the trial treatment.
- •4.Participants cannot be taking 2 or more antihypertensive medications of any class.
- •5.A measure of systolic BP >110 mmHg taken in the previous one-month via home blood pressure monitor, in pharmacy or by clinician;
- •6.Two valid contact details –
- •a.the participant (home address, mobile and email),
- •b.GP or Medical Centre (name, address and phone number).
- •7.Satisfactory completion of online cognitive testing (3 cognitive tests) that meet the software (CREYOS) providers validity indicator to show the test was attempted. Participants must also score above the study threshold (higher scores indicate better performance) on 2 of the 3 tests on at least one of two occasions (i.e. participants are allowed up to 2 attempts at the 3 cognitive tests). If participants score above the threshold on their first attempt an additional attempt will not be offered. The study threshold is set at 1 standard deviation below the mean.
- •8.Agree to take trial medication for a total of: ½ dose of GMRx2 for 30 days, followed by the full dose of GMRx2 for 30 days (i.e. 60 days total duration).
- •9.Agrees to complete online assessments before the study start, during and at the end of the pilot trial.
- •10.Agrees to nominating a ‘study buddy’ for the study, and obtaining the study buddy’s consent for investigators to contact them if required.
- •11.Willingness to have two blood tests as part of the study
排除标准
- •1.A reported diagnosis of Dementia
- •2.Current treatment with anti-dementia medication
- •3.Cognitive test scores below acceptable threshold after two assessments.
- •4.Participants who report having a serious health condition that would compromise their ability to adhere to all of the study procedures
- •5.Reports symptomatic low BP
- •6.Current treatment with excluded or contraindicated medication
- •7.Are unable to provide contact details and GP details
- •8.Participating in another Investigational Medicinal Product Trial that conflicts with RECALL-Pilot
- •9.Unable to provide written informed e-consent.
- •10.Unable to complete online forms
研究者
相似试验
已完成
不适用
Reducing cognitive decline and dementia by lowering blood pressure pilot I studyCognitive declineMental and Behavioural DisordersISRCTN43958304niversity of Dundee/NHS Tayside251
进行中（未招募）
1 期
Towards Onset Prevention of COGnitive decline in adults with Down syndrome (the TOP-COG study) - The TOP-COG studyAlzheimer's disease Down syndromeMedDRA version: 14.0 Level: LLT Classification code 10001896 Term: Alzheimer's disease System Organ Class: 10029205 - Nervous system disordersMedDRA version: 14.0 Level: LLT Classification code 10013616 Term: Down's syndrome System Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2011-001564-21-GBHS Greater Glasgow and Clyde70
招募中
不适用
Development of a novel method to prevent cognitive decline using a "healing smart space" that stimulates the five sensesMild cognitive impairment, behavior and psychological symptoms of dementia, stressJPRN-UMIN000046310Osaka Center for Cancer and Cardiovascular Disease Prevention60
招募中
不适用
Postponing cognitive decline and preventing early unemployment in patients with multiple sclerosis - strengthening the brain and mind (part of the Don't be late! study)MS1000381610012303Multiple SclerosisNL-OMON53491Amsterdam UMC270
已完成
不适用
Towards Onset Prevention of COGnition decline in adults with Down syndrome (the TOP-COG study)Dementia in people with Down syndromeMental and Behavioural DisordersDementia in other diseases classified elsewhereISRCTN67338640HS Greater Glasgow and Clyde (UK)60